Better Weight Loss Means Protecting More Than Fat Loss Alone Why fast results can come with a quieter tradeoff when lean mass drops alongside body fat How muscle-preserving strategies may matter most for…
Promising Research Still Needs Clinical Distance Why obesity-linked cancer biology has pushed metabolic therapies into a more serious scientific conversation What tumor-slowing signals in early studies can suggest, and what they still cannot…
A Label Change Does Not Replace Individual Risk Review Why the 2025 FDA shift changes the conversation around menopausal hormone therapy without removing the need for careful screening How timing, formulation, and route…
When menopause symptoms return after cancer treatment, the path forward needs nuance Older hormone studies still shape today’s caution, even as newer expert consensus pushes for more individualized risk review. Non-hormonal care and…
Weight-loss care is expanding well beyond the incretin pathway FGF21 and GDF15 analogs are drawing attention because they target metabolism, appetite signaling, and liver fat through different biologic routes. This matters most for…